Incyte and Edison Scientific announced a strategic collaboration to employ Kosmos, Edison?s AI scientist, for Incyte?s discovery and development work. Kosmos will be embedded across the Incyte discovery and development lifecycle, enabling continuous learning from translational and clinical data, real-time synthesis of evidence and predictive models of therapeutic performance. The initial deployment will be focused on high-impact use cases in target discovery and validation and translational biology, centered on embedding Edison?s AI capabilities within Incyte?s research workflows to support more efficient exploration of experimental, clinical and biomarker data with the potential to expand across Incyte?s broader R&D organization.

The companies will work together to measure impact on decision quality and long-term pipeline productivity as the system evolves. At the core of the collaboration is a new model for biopharma: one in which a company?s data is not just stored and analyzed, but becomes a compounding asset, used to train AI systems that improve over time and systematically enhance experimental and clinical outcomes.